RenalEndocrinology
Hypercalcaemia (Adult)
Differentiate parathyroid vs malignancy, IV fluids + bisphosphonates, denosumab, treat cause.
Source: Society for Endocrinology; NICE NG12
Step 1 of ~7
info
Assess Severity
Adjusted calcium (corrects for albumin): mild 2.6–3.0 mmol/L; moderate 3.0–3.5; severe >3.5 (medical emergency). Symptoms: 'stones, bones, groans, psychic moans' — renal stones/AKI, bone pain, abdo pain/constipation/nausea, ALOC, polyuria/polydipsia, ECG changes (short QT, J wave, AV block). Bloods: bone profile, U&E, PTH, vitamin D (25-OH), TSH, myeloma screen, urinary calcium, ACE (sarcoid).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Teriparatide · Parathyroid Hormone Analogue (Anabolic)
- Palopegteriparatide · Long-acting parathyroid hormone (1-34) prodrug
- Parathyroid hormone (rhPTH 1-84) · Recombinant human parathyroid hormone
- Teriparatide · Parathyroid Hormone Analogue (Anabolic Bone Agent)
- Denosumab · Anti-RANKL Monoclonal Antibody
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.